FocalTherics (NASDAQ:FOCL) Stock Now Rated “Hold” by Wall Street Analysts

FocalTherics (NASDAQ:FOCL) has been given an average recommendation of “Hold” by the five analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $7.75.

FOCL has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a report on Tuesday, August 25th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a research note on Friday, August 14th. Mizuho began coverage on shares of FocalTherics in a report on Friday, July 17th. They set an “outperform” rating and a $15.00 target price on the stock. Wall Street Zen lowered shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of FocalTherics in a research note on Monday, August 17th.

FocalTherics Price Performance

Shares of FOCL opened at $4.11 on Wednesday. The business’s 50-day moving average is $4.25. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.38 and a current ratio of 1.60. FocalTherics has a 52-week low of $1.82 and a 52-week high of $6.40.

FocalTherics (NASDAQ:FOCL) last issued its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The company had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%. Sell-side analysts anticipate that FocalTherics will post -0.82 earnings per share for the current year.

Insider Activity

In other news, Director David Horn purchased 10,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were purchased at an average price of $4.75 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director owned 10,000 shares in the company, valued at $47,500. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Fran Schulz purchased 10,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was purchased at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the director owned 15,100 shares of the company’s stock, valued at approximately $71,725. This trade represents a 196.08% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders bought 116,000 shares of company stock worth $551,000. Company insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On FocalTherics

An institutional investor recently raised its position in FocalTherics stock. Rock Springs Capital Management LP raised its holdings in FocalTherics (NASDAQ:FOCL) by 7.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,378,000 shares of the company’s stock after acquiring an additional 91,500 shares during the period. Rock Springs Capital Management LP owned approximately 3.68% of FocalTherics worth $5,126,000 at the end of the most recent reporting period. 62.74% of the stock is owned by institutional investors.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.